A Massachusetts-based start-up uses biochemical reactions to visualize cancer and improve lumpectomies. Howard Hechler, CEO of Lumicell, recognizes the constraints of current techniques and presents the start-up’s solution LumiSystem, a combination of the imaging agent LUMISIGHT and Lumicell Direct Visualization System (DVS), as a way to detect #cancer that otherwise would go undetected. Here's how Lumicell is shedding light on residual cancer: https://bit.ly/4fI4fuU #medtech #medicaldevices #startups
MedTech Strategist’s Post
More Relevant Posts
-
CEO at twinzo | Digital Twins | >119k follows | Helping Organizations That Seek Operational Excellence to Be More Effective
For a lung cancer scan, a 60-second breath hold was needed. Now, compare it with a scan with a single breath with a 6-second hold. A significant improvement in cancer treatment 💪 Credit Peter Schardt, Adam Strzelecki, by Varian and Siemens Healthineers ----------- Follow Michal Ukropec for more 3D, digitization, and Industry 4.0 trends | #innovation #startup #digitaltwin
-
A few weeks ago, I had the pleasure of interviewing Karine Clauwaert, CEO of ABSCINT. 🧬 Abscint is a biotech and clinical-stage molecular imaging company dedicated to developing innovative diagnostics using single-domain antibodies. 💊Their mission? To better understand breast cancer and improve treatment outcome. 📹 In this short video, Karine explains what Abscint is, how the company achieved rapid growth in a short time, and why, according to her, there are fewer women CEOs than men, as well as the importance of achieving gender balance in a company. Thank you, Karine, for your time and for sharing your insights 😊 https://lnkd.in/gVehKJpd #interview #biotech #brussels #CEO #women
📷 A few weeks ago, we set out to shine a spotlight on some of the incredible startups and residents in our community 👥. We’re kicking things off with a portrait of Karine Clauwaert, CEO of ABSCINT. ABSCINT is a clinical-stage molecular imaging company developing innovative diagnostics using single-domain antibodies. The goal of Abscint ? Better understanding breast cancer to treat it more effectively 🎗️. Take a moment to listen to her inspiring story! #testimonial #startup #anderlecht #cancer #diagnostic
-
🎥 What do yellow fingers and lung cancer have in common? At first glance, it might seem like yellow-stained fingers could cause lung cancer. But as science dug deeper, the real story turned out to be far more fascinating—and a perfect example of how confounding can twist the tale of cause and effect. Our new #metalens video breaks down this classic misconception and highlights the importance of study designs skills and why interpreting associations requires careful thought. 🤔 👉 Watch the full video by Taulant Muka, MD, MPH, PhD, PD #StudyDesign #EssentialResearchSkills #EvidenceBasedMedicine #HealthcareProfessionals #CriticalThinking #Confounding #Research
-
Founder & Managing Director @ M-B-V-C 🦄 ★ Venture Consultant ★ Entrepreneur ★ Scientist ★ Experienced C-level Manager, Managing Director & Board Member ★ Harvard Medical School Alumnus ★ University Lecturer
Hemerion Therapeutics was just listed within one of the Top 100 start-ups worth investing in. I could not agree more. What's more and needs to be stressed: Hemerion is pushing the limits and venturing into entirely novel grounds as regards therapeutic modality and treatment approach for #glioblastoma, a devastating disease with very bad outcome prognosis, highest relapse-rates, and close to no reasonable therapeutic options available when it comes to efficacy criteria. Invest now. Further info via the article below: https://lnkd.in/eHuATvGk #cancer #therapy #innovation #startup #venture #invest #clinicalimpact
-
Content that sparks action | Copywriter & Lead Gen Strategist | Odoo x AI | Campaigns that convert
😲A tiny 6mm tumor hiding in plain sight, missed by doctors... but not by AI! Early detection saves lives. Our blog dives into the #NHS 's groundbreaking pilot using AI to revolutionize breast cancer screening. Explore the details in our blog👀 https://buff.ly/3xllW1T ❤️🩹Don't settle for "good enough" in healthcare. Let's discuss solutions. www.aiofficer.co #ai #aiinhealthcare #breastcancer #NHS #miaai #aitools #earlydetection #cancerawareness #futuretrends #techtrends #startups
-
-
Outpace Bio Secures $144M in Series B Funding for AI-Enhanced Cancer Therapy - Funding and Investors: Outpace Bio raised $144M in Series B financing, with contributions from RA Capital Management, Qatar Investment Authority, and other investors, bringing total funding to around $200M. - Focus and Leadership: Led by Marc Lajoie, Outpace Bio develops engineered T cell therapies using AI for treating solid tumors. - Product Development: The financing will support advancing T cell product candidates, including OPB-101, targeting ovarian and other cancers, with clinical trials expected in 2025. Subscribe to our daily newsletter here for more AI news https://lnkd.in/dV8hV7cC #AI #Healthcare #VentureCapital #Innovation #Technology #bigdata #ArtificialIntelligence #Futurism #Entrepreneurship #fundraising
Outpace Bio Secures $144M in Series B Funding for AI-Enhanced Cancer Therapy
http://eksentricity.ai
-
Check out this latest episode of The Dish for Johannes Fruehauf's conversation with the thoughtful CEO & Co-Founder of Matrisome Bio!
It's time to Dish!! 🧫🔬 The latest full episode of our new video series, 'The Dish with Johannes' just dropped on our Youtube channel! Full episode here 👉 https://lnkd.in/e9WvUyiA In this episode, Johannes Fruehauf sits down with Noor Jailkhani, CEO & Co-Founder of Matrisome Bio to discuss her transition from academic research to launching a startup. Noor doesn’t just share her learnings—she drops some powerful lessons and shows us her company’s bold, game-changing approach to cancer treatment. #TheDish #innovation #oncology #Matrisome #metastatictumors #CEO #founder #startup
-
Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
🚀 Precision Oncology Just Got a Boost! 🧬 OneCell Diagnostics Inc. has raised $16M in a Series A round led by Celesta Capital, with support from Tenacity Ventures, Cedars Sinai, and others! This funding accelerates the U.S. launch of their groundbreaking OncoIndx Ikon liquid biopsy, a test that analyzes DNA, RNA, and cell surface proteins from circulating tumor cells (CTCs) in a single blood draw. With operations in Mumbai and Cupertino, partnerships with Harvard University and Stanford University, and nearly 10,000 patients already tested in India, OneCell is redefining personalized cancer care. 💡 James Rothman, Nobel laureate, joins their board to further this mission. #PrecisionOncology #LiquidBiopsy #CancerCare #HealthcareInnovation #SeriesAFunding
-
Inevitable rise of AI
A team led by NCI researchers has developed an artificial intelligence (#AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. Learn more: https://go.nih.gov/dQR5JAY
-
-
AI is going to revolutionize the way we approach healthcare, offering truly personalized medicine.
A team led by NCI researchers has developed an artificial intelligence (#AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. Learn more: https://go.nih.gov/dQR5JAY
-
